EVOTEC SE INH O.N.
Commented by Fabian Lorenz on December 4th, 2024 | 07:10 CET
CAUTION with Bayer! Is Evotec facing a SLUMP? 123fahrschule stock with 200% POTENTIAL?
After convincing quarterly figures, analysts have reaffirmed their "Buy" recommendations for the 123fahrschule share. The development of the operating cash flow is seen as particularly positive. Revenues and profits are expected to increase significantly in the coming years, with experts estimating the fair value of the stock to be more than 200% above the current level. Evotec remains under pressure. Following the failed acquisition, a board member is now also leaving the Company. Analysts are divided: will the share price rise to EUR 14 or fall to EUR 4? And what is Bayer doing? According to analysts, the shaken pharmaceutical and agrochemical giant is facing a challenging year ahead. Will margins fall again in 2025? Will the share price follow suit?
Read
Commented by Armin Schulz on December 2nd, 2024 | 07:20 CET
Evotec, Vidac Pharma, BioNTech – Cancer research: The gold mine in the portfolio
Investing in publicly traded companies active in oncology research offers promising returns and long-term stability. The oncology market is one of the fastest-growing sectors in healthcare and benefits from an ever-increasing demand for innovative and personalized cancer therapies. Advances such as CAR-T cell therapies and antibody-drug conjugates are revolutionizing treatment options and creating new opportunities for companies and investors. At the same time, the sector is characterized by a low dependence on economic fluctuations and a high level of dynamism in mergers and acquisitions. With long-term trends such as an aging population, this market offers solid prospects for investors. We take a look at three promising companies.
Read
Commented by Fabian Lorenz on November 28th, 2024 | 07:30 CET
PRICE SURGE or SELL-OFF: Buy BioNTech? Is Evotec on the verge of a slump? BioNxt Solutions share on the brink of a breakout?
Price opportunity with BioNxt! If the innovative biotech stock breaks out of its sideways movement since September, a quick 50% gain could be possible. In any case, things are going well operationally. The Company is developing next-generation drug delivery systems. The Evotec share is not for the faint-hearted. After the price jump following the takeover offer, a sharp drop followed. Analysts see the fair value of the biotech company well below the current price. Will takeover speculation continue? The BioNTech share has avoided slipping below EUR 100. Analysts view the data on the breast cancer candidate positively and recommend buying.
Read
Commented by André Will-Laudien on November 27th, 2024 | 07:00 CET
Biotech in focus! The 2025 blockbusters: Pfizer, BioNTech, Nyxoah, Valneva or Evotec - Who will take off?
The Q3 figures have now been processed. In the shadow of the tech giants on the Nasdaq, biotech stocks are currently being neglected. However, it is important to note that as pressure on the international economies increases, so does the likelihood of interest rate cuts by the central banks. Many investors have been underweight in biotech for quarters, prioritizing other sectors. All of this could be reversed in 2025. An early positioning with the most important protagonists seems promising. We are picking the best opportunities for you from the "Advent calendar."
Read
Commented by André Will-Laudien on November 25th, 2024 | 07:00 CET
Takeovers – The 200% opportunities for 2025! Speculate now on the turnaround for Evotec, BioNxt, Bayer and Nel ASA!
The DAX 40 index is going from strength to strength, following the huge wave of buying since the US election. High-tech and defense stocks are leading the charge. Contrary to this positive trend, biotech stocks have so far been ignored. However, since interest rates are likely to be lowered for the foreseeable future due to the weakening economy, the time of the research-intensive life sciences industry will soon return. There are takeover rumors about Evotec. BioNxt is currently undervalued, and Bayer should be among the winners next year after successful restructuring efforts. It is worth taking a closer look.
Read
Commented by Fabian Lorenz on November 20th, 2024 | 08:15 CET
Takeover battle and soaring profits! Evotec, Bayer, Saturn Oil + Gas
A bombshell announcement came from Evotec late last week. US biotech company Halozyme Therapeutics is offering EUR 11 per Evotec share. Evotec was not informed in advance and seems to be preparing to fend off the takeover. Analysts believe the share price has moved far away from its fundamental value. So, should investors sell the stock now? Experts suggest investors should buy shares of Saturn Oil & Gas. The mid-sized oil producer from Canada is expected to be among the winners under the upcoming Trump administration and will likely soon be paying an attractive dividend. The stock has clear catch-up potential. Meanwhile, analysts are significantly reducing the target price for Bayer. Is there a chance of a turnaround at the agricultural and pharmaceutical giant?
Read
Commented by Armin Schulz on November 20th, 2024 | 07:00 CET
Evotec, Nyxoah, Bayer – A lot of excitement in the healthcare industry
The healthcare sector is currently abuzz with activity. Evotec is the focus of a potential takeover by the US company Halozyme, which has caused the shares of the German biotech company to skyrocket. At the same time, the Belgian medical technology company Nyxoah expects to receive FDA approval soon for its Genio system for the treatment of sleep apnea, which would pave the way for its market entry in the US. Bayer, on the other hand, disappointed with its latest quarterly figures, which showed a significant decline in revenue and EBITDA, leading to a slide in its share price. We take a closer look at these three companies.
Read
Commented by André Will-Laudien on November 14th, 2024 | 07:15 CET
The acquisition carousel is gaining momentum! Evotec, Vidac Pharma, BioNTech, and Formycon in focus
The biotech sector is in the spotlight again today. Triton's entry into Evotec means that another deal is in the works, and investors should now take notice. Many still remember MorphoSys, where there were short-term gains of up to 400% at the beginning of the year. Before that, the stock had been trading with high volumes. Will Formycon or Vidac Pharma be next on the list? Formycon is now getting significantly more attention because the stock switched to the Prime Standard. Evotec has once again disappointed operationally, yet the value has increased by a good 50% in just two months. Those who analyze carefully can profit again. A sharp analytical eye is worthwhile.
Read
Commented by Fabian Lorenz on November 14th, 2024 | 07:00 CET
SHARE PRICES EXPLODE as biotech stocks rise! BioNTech, Evotec, Nyxoah
Is Evotec about to make a quick turnaround? A financial investor is positioning itself for a potential takeover, and the stock surged significantly in the last days. Does this mean that the disappointment over the quarterly figures has been forgotten? Could Nyxoah's stock be the next to skyrocket? The chances of this are good. The medtech company expects FDA approval for the first quarter of 2025 and aims to roll out its main product across the US market next year. Analysts see billion-dollar potential, rapidly increasing revenues, and a favourable P/E ratio. BioNTech shares are also benefiting from a rating upgrade by renowned analysts. The target price has been raised significantly. Could this help the German biotech leader break out of its recent consolidation phase?
Read
Commented by André Will-Laudien on November 13th, 2024 | 07:30 CET
Gold correction - Now is the time to take advantage of the lows! Takeover rumors at Evotec, Desert Gold, Bayer and SMCI
The re-election of Donald Trump as US President had varying effects on the capital markets. The US dollar gained against all currencies, while the hot topic Bitcoin reached new all-time highs of over USD 90,000. The enormous influx of funds into the US stock markets initially slowed down other exchanges. At the same time, the previously sought-after precious metals corrected sharply, putting pressure on mining stocks again. The first shockwaves have now been absorbed, and attention is turning to the real political issues that the White House will now push forward. Defense, industry, and security are in the spotlight, while biotech and green tech remain sidelined. There are some interesting special movements that we will examine here.
Read